Founded in 2011, RS Metrics specializes in analyzing satellite and aerial imagery to deliver critical insights and predictive signals for various sectors, including metals, industrials, retail, and commercial real estate. The company's proprietary technology employs advanced computer vision and machine learning techniques to generate high-quality, actionable data. This data is accessible through user-friendly applications and tools, as well as daily feeds tailored for clients with quantitative needs. RS Metrics also offers customized platforms that provide asset-level insights on environmental, climate, and physical risks, helping organizations make informed decisions and optimize capital allocation. By utilizing a reliable digital infrastructure, RS Metrics streamlines the process of obtaining crucial analytics, enabling businesses of all sizes to effectively monitor and report on their progress.
Covenant Surgical Partners is a privately-held owner and operator of ambulatory surgery centers. Its services include using minimally invasive and robotic technology to screen for colorectal cancers, polyp removal, and surgery of the digestive tract as well as various examinations and diagnoses of the rectum area that enable patients to get proper detection of their diseases.
ACS Partners provides construction services in the commercial and residential markets. ACS' services include renovations to multi-family complexes, student housing complexes, and single-family residential complexes.
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.
The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.
In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.
Soligenix, Inc. is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey, dedicated to developing and commercializing products aimed at treating rare diseases and addressing biodefense needs. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. In the BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma, and SGX942, an innate defense regulator for oral mucositis in head and neck cancer, both in Phase 3 clinical trials. Additionally, it is developing a proprietary oral formulation of beclomethasone for severe gastrointestinal disorders, currently in Phase 1/2 trials. The Public Health Solutions segment focuses on developing a ricin toxin vaccine candidate, RiVax, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections, currently in pre-clinical development. The company was previously known as DOR BioPharma, Inc. before rebranding to Soligenix in 2009.
TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.
Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.
Biomoda, Inc., a development stage company, operates as an in-vitro diagnostics company that develops assays or tests to detect cancer. The company is developing CyPath, an assay for the detection of early-stage lung cancer. Its lung cancer assay tests deep-lung sputum collected from the patient, processes and incubates in the CyPath molecular marker labeling solution, and scores for cancer cells. Biomoda, Inc. was founded in 1990 and is headquartered in Albuquerque, New Mexico.
SinoHub, Inc. is an electronics company based in Shenzhen, China, that operates globally through two main segments: Integrated Contract Manufacturing (ICM) and Electronic Component Sales and Services (ECSS). The ICM segment specializes in the production of custom, private label mobile phones and tablets. In contrast, the ECSS segment focuses on the sale of electronic components to manufacturers and design houses, along with providing supply chain management services such as warehousing, logistics, and import/export operations. SinoHub also offers a proprietary web-based software platform that streamlines the procurement and management of electronic components, facilitating order tracking, inventory management, and vendor oversight. Founded in 2000, SinoHub serves a diverse clientele, including contract manufacturers, original equipment manufacturers (OEMs), and electronics manufacturing services (EMS) companies, enhancing their efficiency in the competitive electronics market.
VeriTeQ is a technology company focused on animal and emergency identification solutions. Its products are utilized around the world in such applications as pet identification using its patented, FDA-approved implantable microchip; livestock identification and tracking using visual and radio frequency identification (RFID) ear tags; and global positioning systems (GPS) search and rescue beacons for use on aircraft, ships and boats, and by adventure enthusiasts. The company was founded in 1993 and headquartered in Delray Beach, Florida.
CEL-SCI Corporation, founded in 1983 and headquartered in Vienna, Virginia, focuses on the research and development of immunotherapy products to treat cancer and infectious diseases. The company's leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for head and neck cancer. Additionally, CEL-SCI has developed a patented T-cell modulation process known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the immune response against a range of health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and allergies. The company is also working on LEAPS-H1N1-DC, CEL-2000, and CEL-4000 for rheumatoid arthritis, alongside LEAPS COV-19 to address COVID-19. CEL-SCI has partnered with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy initiatives.
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.
It was established in 1994 and is headquartered in Lexington, Massachusetts.
Private Equity Round in 2007
ACE*COMM Corporation provided operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Its OSS solutions were applicable to various networks that include wired, wireless, voice, data, multimedia, and Internet communications networks. ACE*COMM marketed and sold its solutions in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It had strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. The company was founded in 1983 and was headquartered in Gaithersburg, Maryland.
Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
Migo Software, Inc. engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information. Its flagship product, Migo, allows users to synchronize their personalized computing environments, including email, digital media, and other data; and application settings to portable storage devices, such as flash/hard disk drives, smart phones, and MP3 players. The company also offers XP to Vista Easy-Sync Suite that provides a safety net and applications support for users transitioning their data and computing environment to a new or upgraded computer running Microsoft’s Windows Vista Operating System; Registry Repair, which fixes computer problems, such as system lock-ups and freezes; PC BackUp, a disaster recovery tool that simplifies the computer backup process; and Recover Lost Data, an utility for retrieving files. In addition, it provides Digital Vault/Portable Vault, Digital File Shedder, DriveWasher, and Easy PC Transfer that offer a line of backup, system utility, and online security/privacy for the users. Migo Software sells its products primarily through original equipment manufacture partnerships, resellers, and through its Web site in the United States and internationally. The company was formerly known as Powerhouse Technologies Group, Inc. and changed its name to Migo Software, Inc. in 2006. Migo Software is headquartered in Redwood City, California.
Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
BravoSolution SpA specializes in supply management technology software and services tailored for procurement and sourcing applications. The company provides a comprehensive suite of solutions that includes spend analysis to enhance savings and compliance, eSourcing for collaborative sourcing efforts, supplier performance management, and contract management to streamline contract processes. Additionally, BravoSolution offers cloud-based tools such as BravoAlign for procurement alignment and transformation, and BravoAdvantage, which supports organizations in generating procurement initiatives from demand to contract. Their analytics platform, BravoAdvantage Analytics, allows procurement professionals to visualize data and create intuitive reports for stakeholders. BravoSolution also delivers collaboration services across various sectors, including transportation and temporary labor, as well as government solutions focused on spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates additional offices globally and is a subsidiary of JAGGAER, Inc.
Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.